Davos Life Science is pleased to announce the issuance of the following patents covering the “Formulation for Effective Tocotrienol Delivery”:
Australian Patent No. 2015354848
Indian Patent No. 331319
Japan Patent No. 6675413
New Zealand Patent No. 731986
US Patent No. 10,493,055
The patented formulation covers a self-emulsifying drug delivery formulation for improved delivery of Tocotrienols.
This formulation shows an improved bioavailability of Tocotrienols. Davos Life Science commissioned an opened-label, randomised, 4-way cross-over clinical study to compare the bioavailability of DavosLife E3 Bio-Enhanced 20 with a market sample. This study was conducted on 28 healthy volunteers with a dosage of 200 mg Tocotrienols. DavosLife E3 Bio-Enhanced 20 was found to offer 46% higher bioavailability compared to a market sample. Learn more.
Visit www.klkoleo.com/davoslife/patents for details.
Australian Patent No. 2015354848
Indian Patent No. 331319
Japan Patent No. 6675413
New Zealand Patent No. 731986
US Patent No. 10,493,055
The patented formulation covers a self-emulsifying drug delivery formulation for improved delivery of Tocotrienols.
This formulation shows an improved bioavailability of Tocotrienols. Davos Life Science commissioned an opened-label, randomised, 4-way cross-over clinical study to compare the bioavailability of DavosLife E3 Bio-Enhanced 20 with a market sample. This study was conducted on 28 healthy volunteers with a dosage of 200 mg Tocotrienols. DavosLife E3 Bio-Enhanced 20 was found to offer 46% higher bioavailability compared to a market sample. Learn more.
Visit www.klkoleo.com/davoslife/patents for details.
